Clinical trials
ER Positive Breast Cancer clinical trials
Below are recruiting er positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 438 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05608252RecruitingPhase 1/Phase 2
Drug combination for advanced ER-positive, HER2-negative breast cancer
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Boston, MassachusettsAges 18 years+ - NCT05638594RecruitingPhase 2
Neoadjuvant drug study for hormone- and HER2-positive breast cancer
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Shenyang, LiaoningAges 18–75 - NCT05659797RecruitingEarly Phase 1
PET scan test for new ER-positive breast cancer
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Scottsdale, ArizonaAges 18 years+ - NCT05720260RecruitingPhase 2
Test immunotherapy plus hormone therapy and an AKT blocker
This trial tests whether combining immunotherapy, hormone therapy, and an AKT-blocking drug can control ER-positive advanced breast cancer in women whose cancer is resistant to hormone treatment. It may help shrink tumors and slow disease by targeting several pathways at once.
TaipeiAges 20 years+ - NCT05722795Recruiting
Imatinib to change triple-negative breast cancer to ER-positive
This trial studies whether imatinib (a pill medicine) can “convert” triple-negative breast cancer into an ER-positive type, which may change how the cancer behaves. If the conversion happens, it could open the door to more treatment options in the future.
GothenburgAges 18 years+ - NCT05736367Recruiting
Study tumor metabolism in certain types of breast cancer surgery
This study looks at how breast cancer cells use energy and nutrients in hormone-receptor positive, HER2-negative tumors during planned surgery. It may help researchers understand the cancer better by comparing tumor tissue with nearby normal tissue.
New Brunswick, New JerseyAges 18 years+ - NCT05766410RecruitingPhase 2
Testing three CDK4/6 pills to change the immune response
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
TaipeiAges 20 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05816655RecruitingPhase 2
Test two hormone treatment combinations for metastatic breast cancer
This Phase 2 study compares two combinations of hormone-blocking drugs plus an anti-cancer targeted pill to see which works better for hormone-receptor positive, HER2-negative metastatic breast cancer. It may help by finding a more effective treatment plan when the cancer has spread.
SeoulAges 19–80 - NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT05846789RecruitingPhase 2
Chemotherapy with or without tocilizumab for breast cancer
This Phase 2 trial tests whether adding tocilizumab (a drug that targets inflammation signals) to standard chemotherapy helps people with triple-negative or ER-low metastatic or locally recurring breast cancer. It’s for adults who have had up to two prior treatments for metastatic disease and who can receive standard chemo.
Atlanta, GeorgiaAges 18 years+ - NCT05861271RecruitingPhase 2
Adjuvant pyrotinib plus capecitabine for tiny HER2 breast cancer
This trial studies whether adding pyrotinib and capecitabine after surgery can lower the risk of cancer coming back in people with very small, lymph-node–negative, HER2-positive breast cancer. It’s for patients who fit specific tumor size and HER2 test results and who can safely take chemotherapy-like medicines and stay on contraception during treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05868226RecruitingPhase 1
Early cancer drug study for adults with advanced tumors
This Phase 1 study tests early (first-in-program) cancer medicines in people whose cancer has not been adequately controlled. It helps researchers learn the safest dose and early signs of whether the treatment may work for different tumor types and treatments.
Birmingham, AlabamaAges 18 years+ - NCT05900206RecruitingPhase 2
Trastuzumab deruxtecan vs standard chemotherapy before breast surgery
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
MalmöAges 18 years+ - NCT05919108RecruitingPhase 2
Neratinib before surgery for HER2-mutated invasive lobular breast cancer
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05935150Recruiting
Skipping lymph node surgery in early breast cancer
This trial studies whether you can safely avoid a lymph node biopsy in the armpit for early breast cancer when scans and exams look negative. It may reduce surgery-related side effects while still keeping cancer care on track.
Nanjing, JiangsuAges 18–70 - NCT05982093RecruitingPhase 2
Elacestrant with or without triptorelin for premenopausal breast cancer
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
Badalona, BarcelonaAges 35 years+ - NCT05982496RecruitingPhase 2
PET/MRI scan for certain breast cancer types
This trial is studying if a special PET/MRI scan using a tracer called 18F FES can help doctors decide the best treatment for people with Luminal A or hormone-receptor-positive lobular breast cancer. The scan looks at estrogen receptors to see if your cancer might respond to hormone therapy.
Milan, MIAges 18 years+ - NCT05989828RecruitingPhase 1
Engineered immune cells for advanced triple-negative breast cancer
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06000917RecruitingPhase 2
Study of combination therapy before surgery for ER+/HER2+ breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT06001086RecruitingPhase 2
Disitamab Vedotin plus Pyrotinib for HER2-positive early breast cancer
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
Nanjing, JiangsuAges 18 years+ - NCT06064812RecruitingPhase 1/Phase 2
Testing a new drug for advanced ER-positive breast cancer
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
Hefei, AnhuiAges 18 years+
Hear when a new ER Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er positive breast cancer?
- Yes. Clin2 currently lists 438 recruiting er positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-positive Breast Cancer
- Hormone-receptor-positive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Node-positive Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.